advertisement
Abstract #6830 Published in IGR 4-1
The latanoprost monotherapy survey in New Zealand, 2000
Elder M; Mora JClinical and Experimental Ophthalmology 2001; 29: 368-369
BACKGROUND: A state subsidy for latanoprost has been recently introduced. It is subject to several conditions including that it should only be used as monotherapy. METHOD: A prospective survey of all New Zealand ophthalmologists was undertaken to determine the outcome of the widespread trial of latanoprost monotherapy. The return rate was 82%. RESULTS: Of 2900 patients on latanoprost nation-wide, 14.7% were monotherapy failures. Of these, 93% were due to inadequate intraocular pressure control but this sub-group had adequate control on two or more medications in 88%. Ophthalmologists had 635 patients that were not trialed as monotherapy, of which 565 (89%) were due to a perceived risk. CONCLUSION: In those patients treated with latanoprost, 85% were adequately controlled as monotherapy.
Prof. M. Elder, Department of Ophthalmology, Christchurch Hospital, PO Box 4710, Christchurch, New Zealand. mark.elder@cdhb.govt.nz
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)